1. Home
  2. TGE vs CNTX Comparison

TGE vs CNTX Comparison

Compare TGE & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$0.91

Market Cap

50.9M

ML Signal

N/A

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

HOLD

Current Price

$0.52

Market Cap

57.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
CNTX
Founded
2023
2015
Country
France
United States
Employees
166
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.9M
57.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TGE
CNTX
Price
$0.91
$0.52
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.60
AVG Volume (30 Days)
35.5K
1.5M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.43
52 Week High
$4.40
$3.62

Technical Indicators

Market Signals
Indicator
TGE
CNTX
Relative Strength Index (RSI) 44.79 38.71
Support Level $0.91 N/A
Resistance Level $1.22 $0.68
Average True Range (ATR) 0.07 0.04
MACD 0.00 0.01
Stochastic Oscillator 44.14 35.26

Price Performance

Historical Comparison
TGE
CNTX

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: